Cargando…

Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use

Background. Fulminant hepatitis is acute hepatic injury with severe decline in hepatic function manifested by encephalopathy, hypercoagulable state, jaundice, renal failure, hypoglycemia, or a constellation of these symptoms in patients without preexisting liver disease. Etiologies include viral inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Rohan, Kapoor, Nidhi, Chaudhari, Kaustubh Suresh, Scofield, Robert Hal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243380/
https://www.ncbi.nlm.nih.gov/pubmed/32434395
http://dx.doi.org/10.1177/2324709620924203
_version_ 1783537418942545920
author Sharma, Rohan
Kapoor, Nidhi
Chaudhari, Kaustubh Suresh
Scofield, Robert Hal
author_facet Sharma, Rohan
Kapoor, Nidhi
Chaudhari, Kaustubh Suresh
Scofield, Robert Hal
author_sort Sharma, Rohan
collection PubMed
description Background. Fulminant hepatitis is acute hepatic injury with severe decline in hepatic function manifested by encephalopathy, hypercoagulable state, jaundice, renal failure, hypoglycemia, or a constellation of these symptoms in patients without preexisting liver disease. Etiologies include viral infections, hepatotoxic drugs, autoimmune diseases, vaso-occlusive diseases, sepsis, and malignant infiltration. Case Report. A 56-year-old man presented with acute heart failure in the setting of cocaine use. The patient subsequently developed fulminant hepatic failure manifested by acute hypoglycemia, elevated liver enzyme, and worsening liver function, which resolved over 1 week with supportive care. The patient was on β-blocker, which was stopped during the admission. He was again admitted on several different occasion for cocaine-induced acute heart failure but did not develop hepatic failure as his β-blocker was discontinued. Discussion. Cocaine has been known to cause hepatotoxicity in humans. However, our patient developed fulminant hepatic failure in the setting of concomitant cocaine and β-blocker use likely secondary to unopposed α-adrenergic activity and ischemic hepatopathy. The patient did not develop hepatic failure on subsequent admissions with cocaine use after discontinuation of β-blockers.
format Online
Article
Text
id pubmed-7243380
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-72433802020-06-03 Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use Sharma, Rohan Kapoor, Nidhi Chaudhari, Kaustubh Suresh Scofield, Robert Hal J Investig Med High Impact Case Rep Case Report Background. Fulminant hepatitis is acute hepatic injury with severe decline in hepatic function manifested by encephalopathy, hypercoagulable state, jaundice, renal failure, hypoglycemia, or a constellation of these symptoms in patients without preexisting liver disease. Etiologies include viral infections, hepatotoxic drugs, autoimmune diseases, vaso-occlusive diseases, sepsis, and malignant infiltration. Case Report. A 56-year-old man presented with acute heart failure in the setting of cocaine use. The patient subsequently developed fulminant hepatic failure manifested by acute hypoglycemia, elevated liver enzyme, and worsening liver function, which resolved over 1 week with supportive care. The patient was on β-blocker, which was stopped during the admission. He was again admitted on several different occasion for cocaine-induced acute heart failure but did not develop hepatic failure as his β-blocker was discontinued. Discussion. Cocaine has been known to cause hepatotoxicity in humans. However, our patient developed fulminant hepatic failure in the setting of concomitant cocaine and β-blocker use likely secondary to unopposed α-adrenergic activity and ischemic hepatopathy. The patient did not develop hepatic failure on subsequent admissions with cocaine use after discontinuation of β-blockers. SAGE Publications 2020-05-21 /pmc/articles/PMC7243380/ /pubmed/32434395 http://dx.doi.org/10.1177/2324709620924203 Text en © 2020 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Sharma, Rohan
Kapoor, Nidhi
Chaudhari, Kaustubh Suresh
Scofield, Robert Hal
Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
title Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
title_full Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
title_fullStr Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
title_full_unstemmed Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
title_short Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
title_sort reversible fulminant hepatitis secondary to cocaine in the setting of β-blocker use
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243380/
https://www.ncbi.nlm.nih.gov/pubmed/32434395
http://dx.doi.org/10.1177/2324709620924203
work_keys_str_mv AT sharmarohan reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse
AT kapoornidhi reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse
AT chaudharikaustubhsuresh reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse
AT scofieldroberthal reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse